公开(公告)号：US20210094994A1

公开(公告)日：2021-04-01

申请号：US17050341

申请日：2019-04-29

申请人： Baylor College of Medicine

发明人： Andras Heczey ,  Sai Batra ,  Purva Rathi

IPC分类号： C07K14/54 ,  C12N5/0783 ,  C07K14/725 ,  A61K35/17 ,  C07K16/30 ,  A61P35/00

摘要： Embodiments of the disclosure encompass methods and compositions related to targeting of tumor antigen-positive cells with therapy using cells that express a chimeric antigen receptor that targets the tumor antigen-positive cells in the presence of None or more interleukins that enhance efficacy of the tumor antigen-specific chimeric antigen receptors. In specific embodiments, the tumor antigen is glypican-3 and the one or more interleukins are EL-15 and EL-21.

公开(公告)号：US20170281683A1

公开(公告)日：2017-10-05

申请号：US15513900

申请日：2015-09-25

申请人： Baylor College of Medicine

发明人： Andras Heczey ,  Stephen M. G. Gottschalk ,  Leonid S. Metelitsa ,  Gianpietro Dotti ,  Wenpeng Li

IPC分类号： A61K35/17 ,  C12N5/0783 ,  C07K16/28 ,  C07K14/705 ,  C07K16/30

CPC分类号： A61K35/17 ,  A61K2039/505 ,  A61P35/00 ,  C07K14/70521 ,  C07K14/70578 ,  C07K16/28 ,  C07K16/303 ,  C07K2317/622 ,  C07K2317/76 ,  C07K2319/03 ,  C07K2319/74 ,  C12N5/0637 ,  C12N5/0638 ,  C12N5/0646 ,  C12N2510/00

摘要： Embodiments of the disclosure include methods and compositions related to immunotherapy that targets glypican-3. In particular embodiments, immune cells engineered to comprise a chimeric antigen receptor that targets glypican-3 are contemplated, and uses thereof. In particular embodiments, medical conditions that are associated with glypican-3 expression or an overexpression of glypican-3 are treated with GPC3 CARs.